<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <title>OAR@UM Collection:</title>
  <link rel="alternate" href="https://www.um.edu.mt/library/oar/handle/123456789/39056" />
  <subtitle />
  <id>https://www.um.edu.mt/library/oar/handle/123456789/39056</id>
  <updated>2026-04-04T05:29:18Z</updated>
  <dc:date>2026-04-04T05:29:18Z</dc:date>
  <entry>
    <title>Malaria and the traveller</title>
    <link rel="alternate" href="https://www.um.edu.mt/library/oar/handle/123456789/13637" />
    <author>
      <name>Tonna, Antonella</name>
    </author>
    <author>
      <name>Tonna, Ivan</name>
    </author>
    <id>https://www.um.edu.mt/library/oar/handle/123456789/13637</id>
    <updated>2019-10-31T08:27:36Z</updated>
    <published>2005-01-01T00:00:00Z</published>
    <summary type="text">Title: Malaria and the traveller
Authors: Tonna, Antonella; Tonna, Ivan
Abstract: Malaria has reached epidemic proportions. About 40% of the world’s population live in malarious areas. It is estimated that 400 million people are infected by malaria each year and of these, 1-3 million die, mostly children under five years of age. In the year 2000, malaria was estimated to be the cause for the loss of nearly 45 million Disability Adjusted Life Years (DALYs) and this accounts for 13% of all DALYs associated with infectious diseases. Malaria has gained importance in Western Europe, including Malta, mainly due to the increasing tourism to malaria endemic countries. There have been 21 reported cases of malaria in Malta between the years 2000-2003.</summary>
    <dc:date>2005-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Drug-induced peptic ulcer disease</title>
    <link rel="alternate" href="https://www.um.edu.mt/library/oar/handle/123456789/13636" />
    <author>
      <name>Vella, Valerie</name>
    </author>
    <id>https://www.um.edu.mt/library/oar/handle/123456789/13636</id>
    <updated>2018-01-03T15:07:32Z</updated>
    <published>2005-01-01T00:00:00Z</published>
    <summary type="text">Title: Drug-induced peptic ulcer disease
Authors: Vella, Valerie
Abstract: For more than a century, peptic ulcer disease has been a major cause of morbidity and mortality. Peptic ulcer disease is a heterogeneous group of disorders involving the gastrointestinal tract and results from an imbalance between the aggressive forces of gastric acid and pepsin and the defensive mechanisms of the gastric mucosa.</summary>
    <dc:date>2005-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>Ensuring the appropriate use of medicines</title>
    <link rel="alternate" href="https://www.um.edu.mt/library/oar/handle/123456789/13635" />
    <author>
      <name>Cordina, Maria</name>
    </author>
    <id>https://www.um.edu.mt/library/oar/handle/123456789/13635</id>
    <updated>2017-05-25T10:37:51Z</updated>
    <published>2005-01-01T00:00:00Z</published>
    <summary type="text">Title: Ensuring the appropriate use of medicines
Authors: Cordina, Maria
Abstract: The safe and effective use of medicines requires the ongoing collaboration of the various health care professionals involved in patient care. Pharmacists are crucial in ensuring the appropriate use of medicines both in the community and in hospital. The large number of medicines available and the constant efflux of new information, be it safety or regulatory, makes it practically impossible for any one health care professional to be updated on all aspects.</summary>
    <dc:date>2005-01-01T00:00:00Z</dc:date>
  </entry>
  <entry>
    <title>The rise and fall of the COX-2 inhibitors</title>
    <link rel="alternate" href="https://www.um.edu.mt/library/oar/handle/123456789/13634" />
    <author>
      <name>Zammit, Mark L.</name>
    </author>
    <id>https://www.um.edu.mt/library/oar/handle/123456789/13634</id>
    <updated>2018-03-26T13:39:58Z</updated>
    <published>2005-01-01T00:00:00Z</published>
    <summary type="text">Title: The rise and fall of the COX-2 inhibitors
Authors: Zammit, Mark L.
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most widely prescribed groups of medicines in clinical practice, their antiinflammatory, analgesic and anti-pyretic properties making them central to the management of osteoarthritis and rheumatoid arthritis. Gastro-intestinal toxicity represents some of the mostserious adverse drug reactions of this class of drugs. In an attempt to minimize these side-effects, selective cyclo-oxygenase-2 (COX-2) inhibitors were developed. In light of increasing concerns regarding their safety, two COX-2 inhibitors – rofecoxib and valdecoxib were withdrawn from the market in September 2004 and April 2005 respectively. Various restrictions have been also imposed on all the other selective COX-2 Inhibitors.</summary>
    <dc:date>2005-01-01T00:00:00Z</dc:date>
  </entry>
</feed>

